Mikhail Blagosklonny Leading the Fight against Cancer

Mikhail Blagosklonny is currently a professor of Oncology at Rosewell Park Cancer Institute located in Buffalo, New York and Chief Editor of Oncortarget. Blagosklonny has been for many years now at the forefront in researching cancer; its therapies and aging. He is famously known for spearheading the use of Rapamycin a cancer drug that helps increase the lifespan of human beings. Rapamycin is a drug that is commonly used for the prevention of organ transplant rejection. The drug which is also known as Sirolimus is used in the coating of coronary stents and the treatment of a rare lung disease. Rapamycin is also a popular cancer drug. The drug was previously used as an anti-fungal agent, but because of its immunosuppressive and antiproliferative properties, doctors stop using it as an anti-fungal agent.Rapamycin immunosuppressant properties play a very critical role when it comes to organ transplant. During organ transplant the body naturally tends to reject foreign organs. For an organ transplant to be successful doctors, recommend the use of anti-rejection drugs or immunosuppressive drugs. However, most of these drugs have adverse effects on the kidneys, and that’s where Rapamycin scores highly as compared to the other immunosuppressive drugs as it has very minimal toxicity level towards the kidney.

Rapamycin is also best for treating hemolytic-uremic syndrome a condition which results from a combination of anemia, kidney failure, and low platelet count. As a result, a patient suffering from the disease is required to have a kidney transplant where one has to use the immunosuppressive drugs to prevent organ rejection. The drugs due to its toxicity nature to the kidney may affect the new kidney thus the use of Rapamycin is recommended to lower the toxicity level. Another use of Rapamycin is in the treatment of Lymphangioleiomyomatosis (LAM) which is a rare lung disease that affects mature women. Also, the drug is used for coronary Stent coating where it prevents the occurrence of re-stenosis in the arteries after a balloon angioplasty procedure. The antiproliferative properties of Rapamycin are used in the treatment of cancer. The drug helps boost the body immune system towards tumors and promotes tumor regression thereby limiting cancer in patients with an organ transplant. Other uses of Rapamycin include the treatment of Tuberous Sclerosis Complex (TSC), Facial Angiofibromas, Muscular Dystrophy, Alzheimer, Systemic Lupus Erythematosus and increase in person’s longevity among others.

One particular area of interest for Mikhail Blagosklonny is the area of cancer as well as aging. Mikhail is interested in specifically knowing what the relationship between the two is as cancer mostly attacks individuals at old age. Mikhail continues to research the field of oncology with the aim of not only finding a way of treating cancer but also to find a method of treatment that will be affordable to many. In addition, Blagosklonny wants to figure out a way in which cancerous cells can be destroyed without affecting the normal cells that are crucial to recovery.Mikhail has made much progress in the field of medicine and cancer treatment and hopes that his findings will inspire others even to do more in the industry. Mikhail endeavors to see that the treatment of cancer is not a preserve of the wealthy in the society who can comfortably afford the treatment but instead it should be an easy and cost-effective type of treatment that is accessible to all regardless of an individual’s financial status.

Leave a Reply

Your email address will not be published. Required fields are marked *